Poor
Not Aligned
Patient Risk:
High
Summary
The claims contain multiple marked absent-from-label efficacy/comparative percentage reductions and formulation/approval statements, plus one claim that is directly contradicted by the provided label excerpts regarding kidney disease suitability.
Category Scores
Accurate Statements
Common side effects of Lipitor include muscle pain, liver damage, and increased risk of diabetes.
Partially supported: muscle adverse effects are discussed under Skeletal Muscle (5.1) and liver enzyme abnormalities under Liver Dysfunction (5.2); diabetes as an adverse reaction is mentioned in SPARCL results within 6.1.
Unsupported Statements
Lipitor (atorvastatin) has been shown to reduce LDL cholesterol levels by an average of 38–45% in patients with high cholesterol.
No label support for the specific average LDL-C reduction range (38–45%) is present in the provided label excerpts.
A study comparing simvastatin (Zocor) and Lipitor reported a mean LDL cholesterol reduction of 43.1% for Lipitor versus 35.6% for simvastatin in patients with high cholesterol.
No label support for these specific comparative percentage reductions is present in the provided excerpts.
A study comparing Lipitor and rosuvastatin (Crestor) reported a mean LDL cholesterol reduction of 43.1% for both medications in patients with high cholesterol.
No label support for this specific comparative result is present in the provided excerpts.
A study comparing Lipitor and pravastatin (Pravachol) reported a mean LDL cholesterol reduction of 42.1% for Lipitor versus 34.5% for pravastatin in patients with high cholesterol.
No label support for this specific comparative result is present in the provided excerpts.
Lipitor was first approved by the FDA in 1997.
FDA approval date is not supported by the provided label excerpts.
Lipitor was described as having efficacy that has been well-documented in numerous studies.
No label support for this general characterization is present in the provided excerpts.
Lipitor is available in generic form.
Generic availability/formulation status is not supported by the provided label excerpts.
Contradictions
High
AI Statement
Lipitor may not be suitable for individuals with kidney disease because it can increase the risk of kidney damage.
Label Reference
2.5 Dosage in Patients With Renal Impairment and 5.1 Skeletal Muscle (renal impairment described as a risk factor for rhabdomyolysis/renal failure in the warning context, not as a reason to generally state it is not suitable).
Important Omissions
No evaluation of boxed warning, full contraindications, or pregnancy/nursing statements was performed because no corresponding claims were provided in the extracted claim list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
At least one claim is directly contradicted by the provided label excerpts regarding renal impairment suitability framing, and multiple efficacy claims lack label support, which can lead to inaccurate expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple efficacy/comparative LDL-C percentage reduction claims are absent from provided label support, and one kidney disease suitability claim is contradicted by the provided label excerpts.
Suggested Improvement
Remove or revise absent-from-label quantitative and comparative percentage reduction statements, remove approval-date and generic-availability assertions unless explicitly supported, and correct the renal impairment-related suitability framing to align with the provided label sections (2.5 and 5.1).